Abstract:Abstract Background: Glioblastoma (GBM) is the most common and aggressive form of brain tumor, characterized by a poorly accessible microenvironment that render it notoriously hard to treat. The insufficient treatment success is, in large parts, due to its tremendous molecular heterogeneity, which affects the overall prognosis and response to therapies. The significant intra- and inter-tumor microenvironment (TME) composition heterogeneity plays a crucial role in GBM progression. Mostly due to this high, multifactorial immunosuppression occurring in the microenvironment, the efficacy of immunotherapy in GBM is low. Focusing on characterizing the components of different TMEs to evaluate their molecular and cellular component heterogeneity has a significant advantage to target group of cancer patients that would normally be resistant to immunotherapy. Methods: Deep spatial transcriptomics profiling was performed on non-treated glioblastoma human tissue microarrays (TMA) using NanoString's GeoMx Digital Spatial Profiler (DSP). 6 tumor tissues from 6 different patients were hybridized and analyzed with the Whole Transcriptomic Atlas (WTA) panel that includes 18,000 genes. Three regions of interest (ROIs) were selected per tissue sample. All the statistical analysis were performed with GeoMx® DSP Analysis Suite. Cell deconvolution using the SpatialDecon® algorithm (Nanostring®) was then performed to estimate mixed cell type abundance in the spatially-resolved gene expression defined segments. Results: Spatial transcriptomic analyses revealed that glioblastoma tumors varied dramatically in their global gene expression profiles and suggested the existence of differential gene expression among the tumors highlighting the inter-tumors heterogeneity of glioblastoma. Interestingly, different areas of the same tumor did not display distinct molecular profiles. Upregulation of stromal collagen genes was significantly detected in some patient specifically the fibrillar collagens type I, III and VI. Those findings indicated excessive collagen depositions in the surrounding of the tumor for some patient characteristic of tumor progression and involvement of cancer associated fibroblasts (CAFs) in the dysregulated collagen turnover leading to tumor fibrosis. Conclusion: As a cold tumor, malignant glioma has strong immunosuppression and immune escape characteristics. The TME provides the “soil” for the survival of malignant tumors, and recent studies have highlighted a major role for cancer-associated fibroblasts (CAFs) in promoting immunotherapy resistance by excluding T cells from tumors in the TME. Here the spatial transcriptomic analyses allowed a better phenotypical stratification of the cancer patient. In some, targeting CAFs would improve the TME and enhance the efficacy of immunotherapy. Citation Format: Sandra Delebecq, Adele Ponzoni, Richard Ruez, Corinne Ramos, Jonathan Stauber. Heterogeneity in glioblastoma tumor microenvironment: Opportunities for new therapies. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 4629.

The Translatome of Glioblastoma Multiforme

The translatome of glioblastoma

Translational Research in Glioblastoma Multiforme: Molecular Criteria for Patient Selection

Abstract 4629: Heterogeneity in glioblastoma tumor microenvironment: Opportunities for new therapies

Upregulation of DNA Metabolism-Related Genes Contributes to Radioresistance of Glioblastoma.

Molecular Characteristics in MRI-Classified Group 1 Glioblastoma Multiforme

Unveiling the Molecular Mechanisms of Glioblastoma through an Integrated Network-Based Approach

Abstract 4638: Integrated proteogenomic characterization of longitudinal glioblastoma

Combined expressional analysis, bioinformatics and targeted proteomics identify new potential therapeutic targets in glioblastoma stem cells

Abstract B009: GBM cells mimic regulatory T cell function to protect the CSC pool from immune surveillance in recurrent GBM

Abstract 2781: GBM cells mimic regulatory T cell function to protect the CSC pool from immune surveillance in recurrent GBM

Patient-based multilevel transcriptome exploration highlights relevant chemokines and chemokine receptor axes in glioblastoma

Glioblastoma multiforme (GBM): An overview of current therapies and mechanisms of resistance

Comprehensive understanding of glioblastoma molecular phenotypes: classification, characteristics, and transition

Highly Multiplexed Spatially Resolved Proteomic and Transcriptional Profiling of the Glioblastoma Microenvironment Using Archived Formalin-Fixed Paraffin-Embedded Specimens

Identification of Novel Transcriptome Signature as a Potential Prognostic Biomarker for Anti-Angiogenic Therapy in Glioblastoma Multiforme

DNAR-13. TARGETING THE DNA DAMAGE RESPONSE IN GLIOBLASTOMA PROPAGATING CELLS: FROM MOLECULAR MECHANISMS TO PRECISION MEDICINE

Metabotropic Glutamate Receptors Type 3 and 5 Feature the “NeuroTransmitter-type” of Glioblastoma: A Bioinformatic Approach

BIOM-20. PROTEOMICS PROVIDES POTENTIAL THERAPEUTIC APPROACHES TO GLIOBLASTOMA TREATMENT: RESULTS FROM THE CLINICAL PROTEOMICS TUMOR ANALYSIS CONSORTIUM (CPTAC)

Alterations in Molecular Profiles Affecting Glioblastoma Resistance to Radiochemotherapy: Where Does the Good Go?

Analysis of the Mechanism Underlying Radiotherapy Resistance Caused by Oligodendroglia Cells in Glioblastoma by Applying the Single-cell RNA Sequencing Technology